Volume 11, Number 7—July 2005
Dispatch
New Lymphogranuloma Venereum Chlamydia trachomatis Variant, Amsterdam
Table
Clinical data | MMA+ |
MMA– |
||||
---|---|---|---|---|---|---|
(2002 and 2003) |
(2003) |
|||||
C. trachomatis |
C. trachomatis |
|||||
L2b | Non-LGV | Total | L2b | Non-LGV | Total | |
No. patients | 32 | 12† | 44 | 13 | 17‡ | 30 |
Anal discharge | 11 | 3 | 14 | 4 | 2 | 6 |
Genital ulcers | 3 (L2b) | 1 (Treponema pallidum) | 4 | 0 | 1 (HSV-2) | 1 |
Lymphadenopathy | 4 | 0 | 4 | 2 | 2 | 4 |
Mean no. infections with sexually transmitted diseases | 8.3 | 5.8 | 7.8 | 7 | 4.6 | 5.8 |
Known HIV+ | 24 | 6 | 30 | 7 | 7 | 14 |
>10 leukocytes by Gram stain | 26 | 3 | 39 | 3 | 6 | 9 |
C. trachomatis lgG ≥200 | 22 | 2 | 24 | 8 | 6 | 14 |
C. trachomatis lgG <200 | 8§ | 10 | 18 | 4¶ | 11 | 15 |
*MMA, mucous membrane abnormalities; C. trachomatis, Chlamydia trachomatis; LGV, lymphogranuloma venereum; Ig, immunoglobulin.
†2 serum samples were not available for testing.
‡1 serum sample was not available for testing.
§Serogroup B, n = 5; intermediate serogroup, n = 5; serogroup C, n = 2.
¶Serogroup B, n = 10; intermediate serogroup, n = 1; serogroup C, n = 6.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.